Keywords : drug delivery, Drug Delivery Technology, Route of administration
- Product Pipeline Review - H2 2011” provides a detailed overview on the QLT Inc.’s research and development focus. The report includes data on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. This report is built using data and information sourced from Global Industries Direct’s proprietary databases, QLT Inc.’s corporate website, SEC filings, investor presentations ...
More »
Search ReportLinker
The Largest Collection of Market Research Reports
» 1.2 Million Industry Reports
» 450,000 Company Profiles
» 850,000 Market Briefings
» 40,000 Country Guides
From +200,000 authoritative sources
- Product Pipeline Review - H2 2011” provides a detailed overview on the QLT Inc.’s research and development focus. The report includes data on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Industries Direct’s proprietary databases, QLT Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from QLT Inc. and market -specific third party sources, put together by Global Industries Direct’s team.
Scope of the Research
- QLT Inc. - Brief QLT Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of QLT Inc. human therapeutic division.
- Detailed Analysis of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of QLT Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the QLT Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Why Should You Get This Report?
- Evaluate QLT Inc.’s strategic position with total access to detailed data on its product pipeline.
- Assess the growth opportunities of QLT Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the QLT Inc.’s Research and Development portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with QLT Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of QLT Inc. and identify potential opportunities in those areas.
Drug Delivery Technology Industry in the United States
Table of Contents
Data table of Contents 2
List of Tables 5
List of Figures 6
QLT Inc. Snapshot 7
QLT Inc. Overview 7
Key Information 7
Key Facts 7
QLT Inc. – Research and Development Overview 8
Key Therapeutic Areas 8
QLT Inc. – Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products – Monotherapy 11
Pipeline Products – Combination Treatment Modalities 12
QLT Inc. – Pipeline Products Glance 13
QLT Inc. – Late Stage Pipeline 13
Phase III Products/Combination Treatment Modalities 13
QLT Inc. Clinical Stage Pipeline Products 14
Phase II Products/Combination Treatment Modalities 14
Phase I Products/Combination Treatment Modalities 15
QLT Inc.–Early Stage Pipeline Products 16
Pre-Clinical Products/Combination Treatment Modalities 16
QLT Inc. – Drug Profiles 17
Latanoprost Punctal Plug Delivery System 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
Lemuteporfin 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
Olopatadine Punctal Plug Delivery System 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
PYY3-36 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
QLT091001 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Verteporfin + Detox-B Adjuvant 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Visudyne + Lucentis 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Visudyne + Lucentis + Dexamethasone 27
Product Description 27
Mechanism of Action 27
R&D Progress 28
QLT Inc. – Pipeline Analysis 29
QLT Inc. – Pipeline Products by Therapeutic Class 29
QLT Inc. - Pipeline Products By Target 30
QLT Inc. – Pipeline Products by Route of Administration 31
QLT Inc. – Pipeline Products by Molecule Type 32
QLT Inc. – Recent Pipeline Updates 33
QLT Inc. - Dormant Projects 35
QLT Inc. - Discontinued Pipeline Products 36
Discontinued Pipeline Product Profiles 36
Atrigel-GHRP-1 36
QLT091568 36
QLT Inc. – Firms Statement 37
QLT Inc. – Operations and Subsidiaries 39
Head Office 39
Other Locations & Subsidiaries 39
Recent Developments 40
May 31, 2011: QLT Announces Issuance Of US Patent For Use Of QLT091001 In Treatment Of Inherited Or Age-Related Retinal Diseases 40
May 31, 2002: QLT and November artis Ophthalmics Announce Positive Recommendations for Visudyne Approval in Europe From European Committee for Proprietary Medicinal Products 40
March 29, 2004: Atrisone (Dapsone Topical Gel) Effective For Treatment Of Acne 41
October 28, 2010: QLT Expands Phase Ib Study Of Oral Synthetic Retinoid Compound 42
August 28, 2002: Visudyne Approved for Occult Subfoveal Choroidal Neovascularisation (CNV) Secondary to Age-Related Macular Degeneration (AMD) 42
July 28, 2009: Qlt Announces Interim Data From A Phase II Clinical Trial And A Device Study For A Punctal Plug Drug Delivery System 43
April 27, 2011: QLT Announces QLT091001 Presentation At ARVO 44
July 26, 2001: November artis Ophthalmics and QLT Announce that Health Canada Approves Expanded Use of Visudyne 45
August 23, 2001: November artis Ophthalmics and QLT Announce FDA Approval of Visudyne as the First Drug Treatment for Pathologic Myopia and Ocular Histoplasmosis 45
April 23, 2002: November artis Ophthalmics and QLT Announce New Drug Application for Visudyne in Japan 46
March 23, 2001: EU Commission Approves Expanded Use of Visudyne 46
June 22, 2010: QLT Announces Final Results From Phase II RADICAL Study Evaluating Visudyne Combination Therapy In Exudative AMD 46
September 20, 2005: QLT announces two year results of visudyne in occult (vio) trial 48
April 20, 2010: QLT Announces Positive Interim Results From Phase Ib Study Of QLT091001 In LCA 48
September 18, 2003: QLT Announces the Completion of Development Milestones in its Continued Efforts to Expand the Availability of Visudyne in Wet AMD March ket 49
May 18, 2006: QLT DELAYS INITIATION OF PHASE IIa ATRIGEL/OCTREOTIDE PROGRAM 50
December 17, 2002: QLT and November artis Provide Update on Phase II Visudyne Studies 50
October 16, 2003: Visudyne Approved in Japan for Treatment of Age-related Macular Degeneration (AMD) 51
December 15, 2009: QLT Inc. Initiates Phase Ib Trial Study Of QLT091001 For The Treatment Of Leber Congenital Amaurosis (LCA) 51
June 15, 2010: QLT Announces Results From Phase IIIb DENALI Study Evaluating Visudyne Combination Therapy 52
October 14, 2004: visudyne in occult(vio) trial to continue to its conclusion at 24 months 52
September 14, 2011: QLT Receives Fast Track Designations For QLT091001 To Treat Both Leber Congenital Amaurosis And Retinitis Pigmentosa 53
February 14, 2006: QLT Inc. Announces Preliminary Findings From Phase II clinical Trial Of Lemuteporfin 54
April 13, 2000: CPMP Recommends Approval in Europe for Visudyne Therapy in the Treatment of Wet AMD 54
April 12, 2000: FDA Approves Visudyne Therapy for AMD 54
March 12, 2009: QLT Announces Completion Of Phase Ia Safety Trial Of Its Synthetic Retinoid Product QLT091001 55
September 10, 2001: November artis Ophthalmics and QLT File Canadian Submission for Expansion of Visudyne Approval 55
March 10, 2010: Qlt Announces Phase II Clinical Trial Results And Development Plans For The Punctal Plug Delivery System 56
February 10, 2011: QLT Receives Positive Opinions For Orphan Drug Designation By European Medicines Agency For QLT091001 57
October 09, 2008: QLT Announces The Initiation Of A Phase I Trial Of Its Synthetic Retinoid Product QLT091001 57
February 09, 2011: Qlt Announces Phase II Clinical Trial Resuls For The Olopatadine Punctal Plug Delivery System (O-PPDS) 58
December 07, 2010: QLT Receives Orphan Drug Designation For QLT091001 To Treat Leber Congenital Amaurosis 58
December 07, 2010: QLT Receives Orphan Drug Designation For QLT091001 To Treat Retinitis Pigmentosa 59
September 07, 2001: November artis Ophthalmics and QLT File Submission with the European Medicines Agency to Expand the Use of Visudyne in AMD 59
February 07, 2001: Favorable Visudyne Clinical Results Announced for Occult AMD and Pathologic Myopia Patients 60
May 06, 2003: New Clinical Data Confirm Role of Visudyne (verteporfin) Therapy as Standard of Care in Choroidal Neovascularization (CNV) due to Age-Related Macular Degeneration (AMD) 60
May 06, 2003: Visudyne Receives Prestigious Award for Innovation in Eye Care 61
April 05, 2006: QLT's Co-Development And Licensing Agreement With Retinagenix For Early Stage Ocular Synthetic Retinoid Program (QLT091001) 61
February 05, 2001: FDA Issues Approvable Letter for Expanded Use of Visudyne 62
May 03, 2011: QLT Announces Positive Results From Phase Ib Trial Of QLT091001 In Subjects With Leber Congenital Amaurosis 62
Financial Deals Landscape 64
QLT Inc., Merger and Acquisition Deal Summary 64
QLT Inc., Pharmaceuticals & Healthcare, Merger and Acquisition Deal Details 65
Asset Transactions 65
QLT Takes Over OT-730 From Othera Pharmaceuticals 65
QLT Takes Over US Rights Of Visudyne From November artis 66
QLT Takes Over Full Rights To Aczone From Astellas 67
Partnerships 68
QLT Ophthalmics Enters Into Co-Promotion Agreement With Quantel Medical And Quantel USA 68
QLT Concludes a new deal With Wilmer Eye Institute 69
Array BioPharma Enters Into Co-Development Agreement With QLT 70
Licensing Agreements 71
QLT Enters Into Licensing Agreement With Reckitt Benckiser 71
QLT Enters Into Licensing Agreement With Retinagenix 72
Asset Transactions 73
Valocor Therapeutics Takes Over Rights To November el Dermatology Programs From QLT 73
QLT Completes Sale Of Aczone To Allergan 75
QLT Completes Sale Of Its Generic Dermatology And Manufacturing Business To Tolmar 76
BioDelivery Sciences International Takes Over BEMA Drug Delivery Technology From QLT 77
Acquisition 79
Tolmar Holding Takes Over QLT USA From QLT 79
QLT Takes Over ForSight Newco II 81
QLT Takes Over Atrix Laboratories 82
QLT Takes Over Kinetek Pharmaceuticals 84
Appendix 85
Methodology 85
Coverage 85
Secondary Research 85
Primary Research 85
Expert Panel Validation 86
Contact Us 86
Disclaimer 86
List of Tables
QLT Inc. – Pipeline by Therapy Area and Indication, H2 2011 9
QLT Inc. – Pipeline by Stage of Development, H2 2011 10
QLT Inc. – Monotherapy Products in Pipeline, H2 2011 11
QLT Inc. – Combination Treatment Modalities in Pipeline, H2 2011 12
QLT Inc. – Phase III, H2 2011 13
QLT Inc. - Phase II, H2 2011 14
QLT Inc. - Phase I, H2 2011 15
QLT Inc. - Pipeline By Therapeutic Class, H2 2011 29
QLT Inc. - Pipeline By Target, H2 2011 30
QLT Inc. – Pipeline By Route of Administration, H2 2011 31
QLT Inc. – Pipeline By Molecule Type, H2 2011 32
QLT Inc. – Recent Pipeline Updates, H2 2011 33
QLT Inc. - Dormant Developmental Projects, 2010 35
QLT Inc. - Discontinued Pipeline Products, 2010 36
QLT Inc., Subsidiaries 39
QLT Inc., Merger and Acquisition Deal Summary 64
QLT Takes Over OT-730 From Othera Pharmaceuticals 65
QLT Takes Over US Rights Of Visudyne From November artis 66
QLT Takes Over Full Rights To Aczone From Astellas 67
QLT Ophthalmics Enters Into Co-Promotion Agreement With Quantel Medical And Quantel USA 68
QLT Concludes a new deal With Wilmer Eye Institute 69
Array BioPharma Enters Into Co-Development Agreement With QLT 70
QLT Enters Into Licensing Agreement With Reckitt Benckiser 71
QLT Enters Into Licensing Agreement With Retinagenix 72
Valocor Therapeutics Takes Over Rights To November el Dermatology Programs From QLT 73
QLT Completes Sale Of Aczone To Allergan 75
QLT Completes Sale Of Its Generic Dermatology And Manufacturing Business To Tolmar 76
BioDelivery Sciences International Takes Over BEMA Drug Delivery Technology From QLT 77
Tolmar Holding Takes Over QLT USA From QLT 79
QLT Takes Over ForSight Newco II 81
QLT Takes Over Atrix Laboratories 82
QLT Takes Over Kinetek Pharmaceuticals 84
List of Figures
QLT Inc. – Pipeline by Therapy Area and Indication, H2 2011 9
QLT Inc. – Pipeline by Stage of Development, H2 2011 10
QLT Inc. – Monotherapy Products in Pipeline, H2 2011 11
QLT Inc. – Combination Treatment Modalities in Pipeline, H2 2011 12
QLT Inc. – Pipeline By Therapeutic Class, H2 2011 29
QLT Inc. - Pipeline By Target, H2 2011 30
QLT Inc. – Pipeline By Route of Administration, H2 2011 31
QLT Inc. – Pipeline By Molecule Type, H2 2011 32
